CZ103793A3 - Solid dosing forms of almocalant, and process for preparing thereof - Google Patents

Solid dosing forms of almocalant, and process for preparing thereof Download PDF

Info

Publication number: CZ103793A3
Authority: CZ; Czechia
Prior art keywords: almokalant; tablets; complex; tablet; dosage form
Prior art date: 1990-12-07

Application number

CS931037A

Other languages

Czech (cs)

English (en)

Inventor

Kjell Andersson

Per Johan Lundberg

Roger Simonsson

Karin Wingstrand

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-12-07

Filing date

1991-12-03

Publication date

1994-02-16

1991-12-03 Application filed by Astra Ab filed Critical Astra Ab

1994-02-16 Publication of CZ103793A3 publication Critical patent/CZ103793A3/cs

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 4
239000007787 solid Substances 0.000 title abstract description 4
229950003699 almokalant Drugs 0.000 claims abstract description 38
ZMHOBBKJBYLXFR-BPNWFJGMSA-N 4-[(2r)-3-[ethyl(3-propylsulfinylpropyl)amino]-2-hydroxypropoxy]benzonitrile Chemical compound CCCS(=O)CCCN(CC)C[C@@H](O)COC1=CC=C(C#N)C=C1 ZMHOBBKJBYLXFR-BPNWFJGMSA-N 0.000 claims abstract description 36
239000002552 dosage form Substances 0.000 claims abstract description 8
238000000034 method Methods 0.000 claims abstract description 7
229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 25
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 22
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 22
229960002796 polystyrene sulfonate Drugs 0.000 claims description 11
239000011970 polystyrene sulfonate Substances 0.000 claims description 11
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
239000007909 solid dosage form Substances 0.000 claims description 10
239000011159 matrix material Substances 0.000 claims description 7
238000002156 mixing Methods 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
229940124531 pharmaceutical excipient Drugs 0.000 claims 4
239000008184 oral solid dosage form Substances 0.000 claims 1
229920000172 poly(styrenesulfonic acid) Polymers 0.000 claims 1
229940005642 polystyrene sulfonic acid Drugs 0.000 claims 1
239000003826 tablet Substances 0.000 description 65
230000000052 comparative effect Effects 0.000 description 22
239000000203 mixture Substances 0.000 description 20
229920000036 polyvinylpyrrolidone Polymers 0.000 description 14
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 14
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 12
238000001035 drying Methods 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 10
239000008187 granular material Substances 0.000 description 10
229940045902 sodium stearyl fumarate Drugs 0.000 description 10
239000000243 solution Substances 0.000 description 10
238000009472 formulation Methods 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
241000234282 Allium Species 0.000 description 7
235000002732 Allium cepa var. cepa Nutrition 0.000 description 7
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
239000012458 free base Substances 0.000 description 7
238000000227 grinding Methods 0.000 description 7
239000001863 hydroxypropyl cellulose Substances 0.000 description 7
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
239000001267 polyvinylpyrrolidone Substances 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
238000007906 compression Methods 0.000 description 5
230000006835 compression Effects 0.000 description 5
239000012729 immediate-release (IR) formulation Substances 0.000 description 5
239000008101 lactose Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
230000002035 prolonged effect Effects 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
230000001186 cumulative effect Effects 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000008213 purified water Substances 0.000 description 4
229920003091 Methocel™ Polymers 0.000 description 3
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000012738 dissolution medium Substances 0.000 description 3
239000003456 ion exchange resin Substances 0.000 description 3
229920003303 ion-exchange polymer Polymers 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000003825 pressing Methods 0.000 description 3
230000002940 repellent Effects 0.000 description 3
239000005871 repellent Substances 0.000 description 3
STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical class C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
239000003929 acidic solution Substances 0.000 description 2
239000003416 antiarrhythmic agent Substances 0.000 description 2
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
229940075579 propyl gallate Drugs 0.000 description 2
235000010388 propyl gallate Nutrition 0.000 description 2
239000000473 propyl gallate Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000007939 sustained release tablet Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
-1 3- (propylsulfinyl) propyl Chemical group 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920003080 Povidone K 25 Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
239000011345 viscous material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Chemical Treatment Of Metals (AREA)

CS931037A 1990-12-07 1991-12-03 Solid dosing forms of almocalant, and process for preparing thereof CZ103793A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9003902A SE9003902D0 (sv)	1990-12-07	1990-12-07	Solid dosage forms of a drug
PCT/SE1991/000815 WO1992010172A1 (en)	1990-12-07	1991-12-03	Solid dosage forms of almokalant and processes for manufacture thereof

Publications (1)

Publication Number	Publication Date
CZ103793A3 true CZ103793A3 (en)	1994-02-16

Family

ID=20381121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS931037A CZ103793A3 (en)	1990-12-07	1991-12-03	Solid dosing forms of almocalant, and process for preparing thereof

Country Status (27)

Country	Link
EP (1)	EP0560821A1 (pt)
JP (1)	JPH06503312A (pt)
CN (1)	CN1063039A (pt)
AP (1)	AP258A (pt)
AU (1)	AU8930791A (pt)
BG (1)	BG97851A (pt)
CA (1)	CA2097178A1 (pt)
CZ (1)	CZ103793A3 (pt)
FI (1)	FI932554A7 (pt)
HU (1)	HUT64217A (pt)
IE (1)	IE914137A1 (pt)
IL (1)	IL100150A0 (pt)
IS (1)	IS3788A7 (pt)
LT (1)	LTIP1717A (pt)
MA (1)	MA22355A1 (pt)
MX (1)	MX9102325A (pt)
MY (1)	MY106776A (pt)
NO (1)	NO932052D0 (pt)
NZ (1)	NZ240731A (pt)
PT (1)	PT99719A (pt)
SE (1)	SE9003902D0 (pt)
SK (1)	SK55693A3 (pt)
TN (1)	TNSN91117A1 (pt)
TW (1)	TW215057B (pt)
WO (1)	WO1992010172A1 (pt)
YU (1)	YU186891A (pt)
ZA (1)	ZA919264B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19602757A1 (de) *	1996-01-26	1997-07-31	Boehringer Mannheim Gmbh	Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
GB9611328D0 (en) *	1996-05-31	1996-08-07	Zeneca Ltd	Pharmaceutical compositions
US6024981A (en) *	1997-04-16	2000-02-15	Cima Labs Inc.	Rapidly dissolving robust dosage form
JP4504467B2 (ja) *	1998-07-30	2010-07-14	佐藤製薬株式会社	口腔内崩壊性錠剤
JP7426685B2 (ja) *	2018-06-14	2024-02-02	株式会社東洋新薬	錠剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8705150D0 (sv) *	1987-12-23	1987-12-23	Haessle Ab	Novel antiarrhythmic agents
IL90245A (en) *	1988-05-11	1994-04-12	Glaxo Group Ltd	Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
SE8902236D0 (sv) *	1989-06-20	1989-06-20	Haessle Ab	Novel polystyrenesulfonate

1990
- 1990-12-07 SE SE9003902A patent/SE9003902D0/xx unknown
1991
- 1991-11-22 ZA ZA919264A patent/ZA919264B/xx unknown
- 1991-11-25 IL IL100150A patent/IL100150A0/xx unknown
- 1991-11-25 TW TW080109239A patent/TW215057B/zh active
- 1991-11-26 NZ NZ240731A patent/NZ240731A/en unknown
- 1991-11-27 YU YU186891A patent/YU186891A/sh unknown
- 1991-11-28 IE IE413791A patent/IE914137A1/en unknown
- 1991-12-02 AP APAP/P/1991/000338A patent/AP258A/en active
- 1991-12-02 MX MX9102325A patent/MX9102325A/es unknown
- 1991-12-03 JP JP4500117A patent/JPH06503312A/ja active Pending
- 1991-12-03 WO PCT/SE1991/000815 patent/WO1992010172A1/en not_active Ceased
- 1991-12-03 HU HU9301670A patent/HUT64217A/hu unknown
- 1991-12-03 CA CA002097178A patent/CA2097178A1/en not_active Abandoned
- 1991-12-03 SK SK55693A patent/SK55693A3/sk unknown
- 1991-12-03 FI FI932554A patent/FI932554A7/fi not_active Application Discontinuation
- 1991-12-03 MA MA22639A patent/MA22355A1/fr unknown
- 1991-12-03 EP EP91920708A patent/EP0560821A1/en not_active Withdrawn
- 1991-12-03 AU AU89307/91A patent/AU8930791A/en not_active Abandoned
- 1991-12-03 CZ CS931037A patent/CZ103793A3/cs unknown
- 1991-12-06 IS IS3788A patent/IS3788A7/is unknown
- 1991-12-06 TN TNTNSN91117A patent/TNSN91117A1/fr unknown
- 1991-12-06 PT PT99719A patent/PT99719A/pt not_active Application Discontinuation
- 1991-12-06 MY MYPI91002267A patent/MY106776A/en unknown
- 1991-12-07 CN CN91112789A patent/CN1063039A/zh active Pending
1993
- 1993-06-04 BG BG97851A patent/BG97851A/xx unknown
- 1993-06-04 NO NO932052A patent/NO932052D0/no unknown
- 1993-12-30 LT LTIP1717A patent/LTIP1717A/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
SK55693A3 (en)	1993-10-06
MY106776A (en)	1995-07-31
CN1063039A (zh)	1992-07-29
BG97851A (en)	1994-04-29
WO1992010172A1 (en)	1992-06-25
TW215057B (pt)	1993-10-21
MA22355A1 (fr)	1992-07-01
HUT64217A (en)	1993-12-28
HU9301670D0 (en)	1993-09-28
IL100150A0 (en)	1992-08-18
CA2097178A1 (en)	1992-06-08
NO932052L (no)	1993-06-04
FI932554L (fi)	1993-06-08
AP258A (en)	1993-06-03
AP9100338A0 (en)	1992-01-31
IE914137A1 (en)	1992-06-17
MX9102325A (es)	1992-06-01
NO932052D0 (no)	1993-06-04
TNSN91117A1 (fr)	1992-10-25
YU186891A (sh)	1994-04-05
NZ240731A (en)	1993-10-26
ZA919264B (en)	1992-08-26
PT99719A (pt)	1992-10-30
LTIP1717A (en)	1995-07-25
EP0560821A1 (en)	1993-09-22
JPH06503312A (ja)	1994-04-14
AU8930791A (en)	1992-07-08
IS3788A7 (is)	1992-06-08
FI932554A7 (fi)	1993-06-08
SE9003902D0 (sv)	1990-12-07

Publication	Publication Date	Title
EP1004298B1 (en)	2004-06-09	Controlled release tablet of bupropion hydrochloride
US6096341A (en)	2000-08-01	Delayed release tablet of bupropion hydrochloride
US6531153B2 (en)	2003-03-11	Composition with sustained release of levodopa and carbidopa
US7749536B2 (en)	2010-07-06	Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
US20090124702A1 (en)	2009-05-14	Pharmaceutical Compositions of Metformin
US20030118647A1 (en)	2003-06-26	Extended release tablet of metformin
JP2003525223A (ja)	2003-08-26	イブプロフェンを含有する活性成分製剤
EP0560822A1 (en)	1993-09-22	Method for the manufacture of a controlled release solid unit dosage form.
JPH0757726B2 (ja)	1995-06-21	高分子量ヒドロキシプロピルメチルセルロースを基剤にした徐放性錠剤
US5149523A (en)	1992-09-22	Polystyrenesulfonate-drug complex and solid dosage forms thereof
WO1990006107A1 (en)	1990-06-14	Sustained release diltiazem formulation
JPH08310969A (ja)	1996-11-26	固形薬品組成物及びその製造方法
EP0266707B1 (en)	1992-01-22	Sustained release labetalol tablet
AP258A (en)	1993-06-03	Solid dosage forms of almokalant and processes for manufacture thereof.
US4940580A (en)	1990-07-10	Sustained release labetalol tablets
EP1458384A1 (en)	2004-09-22	Amlopidine bezylate tablets with improved stability
EP1818048B1 (en)	2009-01-07	Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
US20050042279A1 (en)	2005-02-24	Pharmaceutical formulation comprising more than 15% tamoxifen
JP2000516601A (ja)	2000-12-12	水溶性化合物及びセルロースを含有する粒状物
JPWO2007080776A1 (ja)	2009-06-11	徐放性製剤およびその製造方法
EP1020184A1 (en)	2000-07-19	Sustained release tablets containing bupropion hydrochloride
KR20060130006A (ko)	2006-12-18	경구 서방성 정제
RU2190397C1 (ru)	2002-10-10	Фармацевтическая композиция, содержащая кардиоселективный бета-адреноблокатор, и способ ее получения
KR100540037B1 (ko)	2005-12-29	펠로디핀의 지속성 정제 및 그 제조방법
KR20080093073A (ko)	2008-10-17	지방족 아민 중합체의 약학 제제 및 그 제조 방법